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Abstract	
	
Congestive	 Heart	 Failure	 (CHF)	 is	 a	 progressive	 clinical	 syndrome	 caused	 by	
inability	of	the	heart	to	pump	sufficient	blood	to	meet	the	body’s	metabolic	needs.	The	
treatment	of	CHF	varies	widely	from	patient	to	patient	in	order	to	cause	the	incidence	of	
drug	 related	 problems	 (DRPs).	 Therefore,	 the	 necessary	 of	 DRPs	 identification	 to	
achieve	 patient’s	 therapy	 outcome.	 The	 main	 aim	 of	 this	 research	 study	 was	 to	
determine	 the	 description	 of	 cardiovascular	 pharmacotherapy	 in	 patients	 with	
congestive	heart	failure	as	well	as	to	determine	the	incidence	of	Drug	Related	Problems	
and	to	analyze	the	Drug	Related	Problems	(DRPs).	
This	 research	 was	 conducted	 by	 a	 non‐experimental	 descriptive	 study	 with	
retrospective	data	collection	of	20	medical	record	with	CHF	during	January	to	May	2015,	
then	 the	 DRPs	 were	 analyzed	 using	 literature	 analysis,	 such	 as	 hospital	 standards	 of	
medical	 services,	 Pharmacotherapy	 Handbook	 9th	 edition	 2015,	 New	 York	 Heart	
Association	(NYHA),	Drug	Interaction	Facts	(DIF),	and	Persatuan	Kardiologis	Indonesia	
(PERKI).		
Based	on	this	research	study,	there	were	20	patients	who	had	42	DRPs.	The	DRPs	
consist	of	one	adverse	drug	reaction	 (2.38%),	26	drug	choice	problems	 (61.90%),	one	
drug	 use	 problems	 (2.38%),	 14	 drug	 interactions	 (33.33%),	 and	 no	 dosing	 problems	
were	found.	
	
Keywords:	Congestive	Heart	Failure	(CHF);	Drug	Related	Problems	(DRP);	Panembahan	
Senopati	Public	Hospital;	Inpatients;	Cardiovascular	pharmacotherapy.	
	
	
1. Introduction		
	
Heart	 failure	 is	 in	 the	 fourth	 rank	out	of	 the	 top	10	 leading	 causes	of	 death	 in	
Yogyakarta	 Special	 Province	 (Yogyakarta	 Health	 Office,	 2013).	 Koshman	 et	 al	 (2008)	
explains	 that	 there	 were	 1,977	 patients	 in	 11	 RCT	 studies,	 including	 statistically	
significant	 3	 studies	 showing	 that	 the	 duration	 of	 heart	 failure	 inpatient	 would	 be	
prolonged	if	there	is	no	pharmaceutical	care.	
	
Pharmaceutical	care	was	conducted	a	pharmacist	who	has	a	role	and	function	to	
identify	 Drug	 Related	 Problems	 (DRPs),	 overcomes	 actual	 DRPs	 which	 happen,	 and	
prevents	potential	DRPs	(Adusumilli	and	Adepu,	2014).	
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Based	on	a	 research	 conducted	by	Hadiatussalamah	 (2013)	 related	 to	DRPs	 in	
143	patients	with	congestive	heart	failure,	the	result	shows	that	the	prevalence	of	DRPs	
incidence	 was	 32.87%	 (47	 patients).	 DRPs	 research	 which	 was	 also	 done	 by	 Endah	
(2014)	 in	 congestive	 heart	 failure	 patients	 with	 26	 cases	 (37.14%),	 there	 were	 32	
episodes	 of	 DRPs	 incidences.	 From	 these	 two	 studies,	 it	 it	 can	 be	 seen	 that	 the	
percentage	incidence	of	DRPs	in	patients	with	congestive	heart	failure	is	quite	high,	and	
almost	every	hospital	estimated	that	the	number	is	quite	high.	One	of	them	is	estimated	
to	 occur	 at	 Panembahan	 Senopati	 Bantul	 Hospital	 that	 is	 taken	 as	 the	 study	 site	 by	
researchers.	
	
2. Material	and	Method	
	
2.1	Research	Equipments		
The	equipments	used	 in	the	study	are	data	collecting	sheets,	Pharmacotherapy	
Handbook	 9th	 edition	 year	 2015,	 books,	 journals,	 and	 other	 literatures	 related	 to	
congestive	 heart	 failure,	 drug	 related	 problems,	 medical	 service	 standards	 at	
Panembahan	Senopati	Bantul	Hospital.	
	
2.2	Population	and	Sample	
The	 population	 of	 the	 study	 was	 hospitalized	 patients	 diagnosed	 with	 CHF	 in	
Panembahan	Senopati	Bantul	Hospital	 from	 January	 to	May	2015.	The	samples	are	all	
patient	in	the	population	who	had	met	the	inclusion	criteria.	
	
2.3	Data	analysis	
The	 data	 will	 be	 obtained	 and	 analyzed	 using	 descriptive	 non‐experimental	
methods.	The	data	include:	
 An	 overview	 of	 patient’s	 characteristics	 based	 on	 sex,	 age,	 comorbidities	 and	
inpatient	duration.	
 The	 data	 that	 had	 been	 collected,	 grouped,	 and	 numbered	 as	 well	 as	 the	
presented	results	presented.	
 The	 calculations	 for	 the	percentage	 of	 each	of	 the	DRPs	 identification	done	by	
counting	 the	number	of	 patients	 in	 each	of	 the	DRPs	 then	divided	by	 the	 total	
number	of	existing	DRPs	multiplied	by	100%	(Equation	below).	
	
∑݄݁ܽܿ	ܦܴܲݏ
∑݋ݒ݁ݎ݈݈ܽ	݅݊ܿ݅݀݁݊ܿ݁	݋݂	ܦܴܲݏ ൈ 100%	
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3. Results	And	Discussion	
	
3.1	Characteristics	of	the	Patients	Based	on	Sex	
	
The	 characteristic	 of	 the	 patients	 based	 on	 gender	 is	 presented	 in	 Figure	 1.	
There	were	 incidents	 on	women	as	with	 45%	 (9	patients)	 and	on	men	with	 55%	 (11	
patients)	of	total	patients	100%	(20	patients).	It	means	that	in	this	study	the	prevalence	
of	CHF	in	women	is	lower	than	in	men.	
	
Figure	1.	Characteristics	based	on	sex	
	
Based	cohort	study	in	the	USA,	2‐5	of	1000	people	annually	suffer	from	CHF,	and	
CHF	incidence	in	men	is	higher	than	in	women	(Bui	et	al.,	2011).	
	
3.2	Characteristics	of	the	Patients	Based	on	Age	
	
Based	on	age,	among	20	patients	becoming	the	respondents	could	be	categorized	
in	a	varied	age	range	(Figure	2),	and	the	data	were	taken	based	on	data	from	Data	Center	
and	Information	of	Health	Ministry	(2014).	
	
Figure	2.	Characteristics	based	on	age	
	
The	 percentage	 obtained	 by	 Figure	 2	 shows	 that	 patients	 suffering	 from	 CHF	
were	found	in	patients	with	the	age	range	45‐54	years,	age	55‐64	and	age	65‐74	years.	
Based	 on	 the	 Framingham	Heart	 Study,	 the	 incidence	 of	 heart	 failure	 is	 higher	 in	 the	
elderly	(Bui	et	al.,	2011).	Most	of	the	patients	with	CHF	were	in	the	age	group	of	65	years	
or	more,	while	in	the	age	group	<65	increase	from	23%	to	29%	(Hall	et	al,	2012)	
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3.3 Characteristics	of		the	Patients	Based	on	Morbidities	
	
According	to	the	table	1	it	can	be	seen	that	the	highest	percentage	on	the	group	≥	3	
comorbidities	 (50%),	 meaning	 that	 the	 risk	 of	 complications	 in	 patients	 with	 CHF	 is	
huge.	 The	 morbidities	 	 that	 become	 the	 most	 widely	 experienced	 by	 patients	 in	 this	
study	 were	 Ischemic	 Heart	 Disease	 (IHD)	 or	 Coronary	 Artery	 Disease	 (CAD).	 New	
England	 Journal	 of	 Medicine	 reported	 that	 in	 the	 last	 20	 years	 there	 were	 >	 43	 000	
patients,	and	65%	among	them	suffered	from	CAD	that	becomes	the	main	cause	of	heart	
failure	 based	 on	 24	 multicenter	 studies	 on	 heart	 failure	 therapy	 (Gheorghiade	 et	 al.,	
2006).	
	
												Table	1.	Characteristics	of	Morbidities		
Number	of	Morbidities	 Morbidities Number	of	Patients		 Percentage	
1	Morbidities	 Bronkopneumonia 1 5%	
2	Morbidities		
Hypertension	type	II,		 1	
45%	
chest	pain	obstruction	
SIRS,	hipokalemia 1
Atrial	fibrilasis,		
Acute	bronkhitis	 1	
IHD,	atrial	fibrilasis 1
IHD,	bronkospasme	 1	
IHD,	acute	bronkhitis	 1	
IHD,	atrial	fibrilasis 1
IHD,	gout	artritis 1
Cardiomegali,	DM	type	II	 1	
≥3	Morbidities	
Hypertension	type	II,		
hipoalbumin,	DM	type	II	 1	
50%	
IHD,	hipertension,	DM	 1	
IHD,	hepatitis	A,	hypertension,	DM	 1	
IHD,	vertigo,	GERD 1
Cardiomiopati,	ca	mammae	IV,	shock	septis,		
DM	type	II	 1	
Cardiomegali,	ca	mammae	IV,	candidiasis	oral	 1	
IHD,	atrial	fibrilasis,	hyperurisemia,	GERD 1
IHD,	 DM	 type	 II,	 obesity,	 renal	 failure	 ec	
nefropati,	hypertension	type	II,	ulcer	 1	
IHD,	 shock	 cardiogenic,	 migrain,	 candidiasis	
oral	 1	
IHD,	dilipidemia,	hyperurisemia	 1	
TOTAL	 20	 100%	
	
	
3.4 Characteristics	of	the	Patients	Based	Inpatient	Duration		
	
Patient	characteristics	based	on	Length	of	Stay	(LOS)	or	inpatient	duration	in	the	
study	were	classified	into	2;	those	are	LOS	<	6	days	and	LOS	≥	6	days.	The	percentage	of	
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patients	with	Length	of	Stay	<6	days	was	higher	(55%)	than	in	patients	with	length	of	
stay	≥	6	days	(45%)	(Table	2).	
	
Table	2.	Characteristics	of	the	Patients	Based	on	Length	of	Stay	
	 Length	of	Stay	 Total	 Percentage	
	 <	6	days	 11	 55%	
	 ≥	6	days	 9	 45%	
	 TOTAL	 20 100%
	
	
Bueno	et	al	(2010)	explains	that	during	2006,	there	were	approximately	493,554	
patients	who	were	hospitalized	with	a	diagnosis	of	heart	failure	that	had	been	analyzed.	
The	average	length	of	stay	(LOS)	was	for	6:33	days.	The	criteria	that	affect	the	length	of	
stay	 of	 patients	 in	 the	 study	 varied	 widely,	 and	 the	 most	 significant	 one	 was	 the	
reduction	or	disappearance	of	dyspnea	symptoms.	
	
3.4	Identification	of	Drug	Related	Problems	(DRPs)	
	
DRP	classifications	used	in	this	study	followed	the	classification	of	PCNE	(2006).	
The	results	of	 the	study	are	presented	in	Table	3.	Based	on	Table	3,	DRPs	choice	drug	
problem	 was	 on	 the	 first	 place	 with	 the	 percentage	 61.90%	 (26	 incidents).	 Drug	
interaction	was	the	second	with	a	total	percentage	of	33.33%	(14	incidents).	
	
Table	3,	DRPs	choice	drug	problem	
DRPs	Classification		 Explanation		 Number	 of	
Incidence		 Percentage	
Adverse	 drug	 reaction	
(ADR)	 or	 unexpected	
reaction	
Unexpected	 side	 effect	 (allergic	 or	 non‐
allergic)	
Experienced	toxic	effect	
1	 2.38%	
Drug	choice	problem		
Unsuitable	indicated	drugs.	Unsuitable	drug	
availability.	 Duplication	 on	 therapy	 group	
or	 active	medicine.	 Contraindication	 drugs	
(on	pregnant	or	breastfeeding).	
Non‐therapy	indication.		
26	 61.90%	
Dosing	problem		
Lack	 drug	 dosage	 or	 unsuitable	 dosage	
regiment.		
Too	high	drug	dosage	or	too	often	drug.	
Drug	giving	duration	whether	it	has	slow	or	
fast	response	
‐	 ‐	
Drug	use	problem		 Drug	provision	mistake 1 2.38%	
Drug	interaction		 Potential	or	actual	interaction	 14	 33.33%	
TOTAL	 42	 100%	
	
	
3.4.1	Adverse	Drug	Reactions	
	
Adverse	drug	reactions	or	unexpected	reactions	happened	in	1	 incident;	 it	was	
the	 use	 of	 captopril.	 Captopril	 is	 one	 of	 the	 drugs	 known	 as	 Angiotensin	 Converting	
Enzyme	Inhibitors	(ACEI)	working	on	the	track	of	Renin	Angiotensin	Aldosterone	(RAA)	
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inhibiting	 the	 Angiotensin	 Converting	 Enzyme	 (ACE)	 and	 able	 to	 reduce	 cardiac	
remodeling.	ACE	 inhibition	 is	not	only	affecting	 the	RAA	 lines	but	 also	 influencing	 the	
inactivation	 lines	of	bradykinin	 (Ceconi	 et	 al.,	 2007).	 Inhibited	bradykinin	 inactivation	
can	lead	to	accumulation	of	bradykinin	and	stimulate	chemoreceptors	on	the	respiratory	
tract,	 consequently	 arises	 a	 sense	of	 tingling	 and	 itching	 that	 leads	 to	 cough	 response	
(Golias	et	al.,	2007).	
	
3.4.2	Drug	Choice	Problem	
	
Drug	choice	problem	or	 the	problem	 in	 the	selection	of	drugs	was	 found	 in	all	
patients	who	became	 the	 subjects	 of	 the	 study.	Each	 category	of	 drug	 choice	problem	
was	 found	 in	 the	 same	patient.	The	 results	of	 the	 incidence	of	drug	 choice	problem	 is	
presented	in	Table	4.	
	
	
Table	4.	Incidence	Rate	of	DRPs	on	drug	choice	problem	
Drug	 Choice	
Problem	 Explanation		
Patient’s	
Number		
Numbers	 of	
Patient	
Unsuitable	
indicated	drug		
Alloprinol,	Furosemid 3
11	
Allopurinol,	Ranitidin	 8	,	19	
Allopurinol,	Candistatin 13
Furosemid,	Ranitidin 12,	20
Ranitidin,	Cisplatin	 18	
Allopurinol 9
Furosemid	 5	,	6	
Ranitidin	 16	
Non	 therapy	
indication		
No	digoksin	provision		 1,	 2,	 3,	 6,	 11,	13,	18,	19,	20	
14	Fever	and	Pain		 4	DM	and	ca	mammae	stage	IV	 7	
Cough	with	phlegm	 8,	12
Hyperurisemia	and	cardiogenic	shock	 14	
Duplication		 Valsartan	and	Captopril	 2	 1	
	
	
The	findings	of	the	drugs	that	did	not	follow	the	indication	in	this	study	(Table	4)	
was	on	the	use	of	allopurinol.	However,	the	laboratory	results	did	not	show	increasing	
levels	of	uric	acid	(hyperuricemia).	Provision	of	furosemide	was	not	in	accordance	with	
the	indication	because	the	patient	did	not	experience	edema.	Patients	in	this	study	did	
not	 show	any	 indication	 that	 they	had	 to	get	 therapy	with	 ranitidine	 (this	drug	 is	not	
appropriate	 with	 the	 indication).	 Candistatin	 (Nystatin)	 is	 also	 a	 drug	 that	 is	 not	 in	
accordance	 with	 the	 indications.	 Data	 from	 Alpha	 Diagnostic	 International	 (2011)	
mentions	that	candistatin	is	an	antifungal	that	will	be	effective	against	candidiasis.	The	
patient's	diagnosis	did	not	find	candidiasis	or	other	fungal	infections.	The	next	finding	of	
drug	choice	problem	was	there	was	a	patient	complaining	for	the	fever,	but	there	was	no	
drug	given.	Pain	is	also	one	of	the	main	complaints	of	patients	and	had	not	been	treated.	
In	addition,	other	than	dyspnea	and	edema,	the	symptoms	experienced	by	patients	with	
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CHF	 also	 the	 complaint	 of	 pain	 requiring	 palliative	 therapy	 (Adler	 et	 al.,	 2009).	 The	
findings	 indicated	 that	 there	 was	 no	 further	 therapy	 in	 patients	 with	 hyperuricemia.	
Larina	 et	 al.	 (2011)	 explained	 that	 there	 were	 60%	 of	 CHF	 patients	 who	 were	
hospitalized	experienced	hyperuricemia	as	a	result	of	cardiac	decompensation.	Therapy	
in	patients	with	hyperuricaemia	as	a	 first‐line	of	 the	drugs	 is	 the	drug	 in	 the	group	of	
xanthine	 oxidase	 inhibitors	 such	 as	 allopurinol	 (Khanna	 et	 al,	 2012).	 The	 findings	
showed	duplication	 in	 the	 treatment	group.	Patients	 receiving	 valsartan	and	 captopril	
can	 have	 increasing	 risk	 of	 hyperkalemia	 and	 hypotension	 if	 the	medicines	 are	 given	
together	(Tatro,	2010).	
	
3.4.3	Drug	Use	Problems		
	
Giving	 ceftriaxon	was	 the	 contraindication	 for	patients	 given	 treatment	CaCO3	
and	calcium	polystyrene	sulfonate.	There	 is	possibility	of	 toxicity	 to	the	organs	caused	
by	 the	precipitation	of	 calcium	as	well	 as	 the	possibility	 of	 embolic	 events	 in	patients	
receiving	ceftriaxon,	CaCO3dan	calcium	polystyrene	sulfonate	(Steadman,	2010).	
	
3.4.4	Drug	Interaction		
	
Drug	interactions	become	one	of	the	issues	that	needed	to	be	evaluated	since	the	
adverse	 effects	 can	 arise	 as	 the	 impact	 of	 it.	 The	 results	 of	 the	 incidence	 of	 drug	
interactions	can	be	seen	in	Table	5.	
Table	5.	The	Finding	of	drug	interactions	
Drug	Interaction	 Total	 of	Patient	 Information	
Spironolakton+Valsartan	 1	
Significance:	1	
Onset	slow	interaction	
Severe	rate:	mayor	
Spironolakton+KSR	 1	
Significance:	1
Onset	slow	interaction	
Severe	rate:	mayor	
Captopril+KSR	 2	 Significance:	4Onset	slow	interaction,	Severe	rate	n:	moderate	
Gentamisin+Furosemid	 4	
Significance:	1	
Onset	slow	interaction	
Severe	rate:	mayor	
Allopurinol+Captopril	 8,	 9,	 10,	15,	18,	19	
Significance:	4	
Onset	slow	interaction	Severe	rate:	mayor	
Warfarin+Ceftriakson	 9	 Significance:	2	Onset	slow	interaction,	Severe	rate:	moderate	
Digoksin+Omeprazol	 10	 Significance:	4Onset	slow	interaction,	Severe	rate:	moderate	
Aspirin+Clopidogrel	 17	
Significance:	1
Onset	slow	interaction	
Severe	rate:	mayor	
Warfarin+Allopurinol	 10	 Significance:	4Onset	slow	interaction,	Severe	rate:	moderate	
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The	 first	 finding	 of	 drug	 interactions	 is	 that	 patients	 received	 spironolactone	
therapy,	 valsartan	 therapy	 and	 potassium	 chloride	 therapy	 (Table	 5).	 It	 happens	
because	spironolactone	can	increase	the	levels	of	potassium	serum	with	the	mechanism	
of	 action	 as	 a	 non‐selective	 antagonist	 aldosterone.	 The	 risk	 of	 hyperkalemia	 also	
increased	by	the	use	of	valsartan.	Other	drug	interaction	was	found	in	patients	receiving	
furosemide	 and	 gentamicin.	 Xia	 (2013)	 also	 explained	 that	 there	 were	 17	 mice	
experienced	 impaired	 hearing	 after	 being	 given	 combination	 of	 gentamicin	 and	
furosemide,	 and	 only	 16	mice	 could	 survive.	 Drug	 interaction	was	 also	 seen	 in	 some	
patients	 receiving	 allopurinol	 and	 captopril.	 Tatro	 (2010)	 in	 the	 book	 of	 Drug	
Interaction	Facts	explained	that	interaction	between	allopurinol	and	captopril	should	be	
monitored	toward	hypersensitivity	reactions	in	patients,	but	it	is	not	certain	about	the	
mechanism	of	 interaction.	The	use	of	ceftriaxone	and	warfarin	also	became	the	part	of	
drug	 interactions.	 Baillargeon	 et	 al	 (2012)	 explained	 that	 the	 administration	 of	
antibiotics,	 which	 one	 of	 them	 is	 the	 group	 of	 sefalosforin,	 can	 increase	 the	 risk	 of	
bleeding	in	most	patients	who	also	receive	warfarin	therapy.	Drug	interaction	was	also	
found	 on	 digoxin	 therapy	 and	 omeprazole.	 The	 use	 of	 digoxin	 altogether	 with	
omeprazole	 may	 increase	 the	 absorption	 of	 digoxin	 itself	 caused	 by	 the	 working	
mechanism	 of	 omeprazole	 as	 a	 proton	 pump	 inhibitor	 (Lahner	 et	 al.,	 2009).	 The	 next	
drug	 interaction	 was	 in	 the	 patients	 receiving	 aspirin	 and	 clopidogrel.	 McQuaid	 and	
Laine	(2006)	based	on	meta	analysis	explained	that	the	risk	of	gastrointestinal	bleeding	
increases	in	the	provision	of	low‐dose	aspirin	and	clopidogrel	simultaneously.	
	
Conclusion 
	
Based	 on	 data	 of	 the	 research	 and	 the	 discussion	 identification	 of	 DRPs	 in	
patients	 diagnosed	 with	 Congestive	 Heart	 Failure	 (CHF)	 at	 inpatient	 ward	 of	
Panembahan	Senopati	Bantul	Hospital	January	to	May	2015	period,	it	can	be	concluded	
that	 the	 total	 incidence	 of	 DRPs	 were	 20	 patients	 with	 the	 main	 diagnosis	 of	 CHF	
becoming	 inpatient	 at	 Panembahan	 Senopati	 Bantul	 Hospital	 during	 January	 to	 May	
2015	period	with	42	 events	 consisting	of	 adverse	drug	 reaction	 (ADR)	or	unexpected	
reactions	with	 1	 occurrence	 (2:38%),	 drug	 choice	 problem	with	 26	 events	 (61.90%	 ),	
dosing	problems	with	no	occurrence,	drug	use	problems	with	1	occurrence	(2:38%)	and	
drug	interaction	with	14	incidences	(33.33%).	
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